Clinical Trial Update: A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety of gusacitinib in patients with systemic lupus erythematosus has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Gusacitinib (gusacitinib)

Snippet

Sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: WITHDRAWN